News and Media
MMS Promotes Two Leaders at its Asia Headquarters amid Strong Growth Period
Is among the lowest attrition rates in the pharmaceutical industry regionally Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr....
MMS Partners with University of Findlay to Provide Medical Writing and Clinical Trial Disclosure Courses
Canton, Mich. and Findlay, Ohio (May 1, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that they have partnered with the University of Findlay to provide online medical writing and clinical trial disclosures...
MMS reaches an employee training milestone of 700 pharma industry courses
Canton, Mich. (April 13, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that it has surpassed a training milestone, now with more than 700 training courses available in their learning management system. This...
MMS Selected by Paratek to Support its NDA Submissions for Omadacycline
MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and...
Complimentary Webinar: Optimizing the Use of Clinical Trial Disclosure Systems
MMS is collaborating with the DIA for an upcoming complimentary webinar, “Optimizing the Use of Clinical Trial Disclosure Systems to Meet Complex and Evolving Global Regulatory Requirements.” Learning Objectives Determine key drivers for the use of technology to...
Pfizer Selects MMS as Preferred Provider for Plain Language Summary Writing Support
Pfizer has selected MMS Holdings Inc. (MMS), headquartered in Canton, MI, as a preferred provider for support writing plain language summaries of the results for all its Phase 2 and 3 clinical trials. In advance of implementation of EU Clinical Trial Regulation No....
Emmaus Medical’s New Drug Application for Sickle Cell Disease Recommended for Approval by FDA
Emmaus Life Sciences Inc. (Emmaus) has announced that EndariTM for the treatment of sickle cell disease (SCD) has been recommended for approval by the Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee. In a10–3 vote, the committee recognized that...
MMS Funds $1 Million Zika Vaccine Development Award
Canton, Mich. (March 14, 2016) — MMS Holdings Inc., a specialty data-focused CRO, has announced a $1M award toward the development of a Zika vaccine. The award is being offered as data services to qualified pharmaceutical companies supporting the commercial...
MMS Announces Expansion of Asia Operations In Hyderabad
HYDERABAD (January 26, 2016) — MMS Holdings Inc. (www.mmsholdings.com) is pleased to announce the opening of a new office in Hyderabad, India. The company’s Asia headquarters are located in Bangalore, India and the company’s ability to deliver exceptional quality...
SUBSCRIBE TO UPDATES
Please provide your information to stay informed.
Avery Zimmerman
6880 Commerce Blvd.
Canton, MI 48187 USA
734 245 0310
media@mmsholdings.com
CONNECT WITH US